Supernus Pharmaceuticals Inc (SUPN) : Juncture Wealth Strategies scooped up 30,060 additional shares in Supernus Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Apr 11, 2016. The investment management firm now holds a total of 64,275 shares of Supernus Pharmaceuticals Inc which is valued at $1,048,968.Supernus Pharmaceuticals Inc makes up approximately 0.79% of Juncture Wealth Strategies’s portfolio.
Supernus Pharmaceuticals Inc closed down -0.05 points or -0.31% at $16.32 with 4,02,315 shares getting traded on Friday. Post opening the session at $16.32, the shares hit an intraday low of $15.92 and an intraday high of $16.51 and the price fluctuated in this range throughout the day.Shares ended Friday session in Red.
Other Hedge Funds, Including , Capstone Asset Management Co boosted its stake in SUPN in the latest quarter, The investment management firm added 320 additional shares and now holds a total of 23,080 shares of Supernus Pharmaceuticals Inc which is valued at $376,666. Supernus Pharmaceuticals Inc makes up approx 0.01% of Capstone Asset Management Co’s portfolio.Creative Planning reduced its stake in SUPN by selling 51 shares or 1.62% in the most recent quarter. The Hedge Fund company now holds 3,100 shares of SUPN which is valued at $51,305.
On the company’s financial health, Supernus Pharmaceuticals Inc reported $0.08 EPS for the quarter, beating the analyst consensus estimate by $ 0.06 according to the earnings call on Nov 3, 2015. Analyst had a consensus of $0.02. The company had revenue of $38.59 million for the quarter, compared to analysts expectations of $38.07 million. The company’s revenue was down -26.5 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $0.39 EPS.
Many Wall Street Analysts have commented on Supernus Pharmaceuticals Inc. Supernus Pharmaceuticals Inc was Upgraded by Jefferies to ” Buy” on Feb 8, 2016.
Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company. The Company focuses on developing and commercializing products for the treatment of central nervous system diseases. The Company launched its two products in neurology for the treatment of epilepsy which include Oxtellar XR and Trokendi XR. It is also engaged in developing multiple product candidates in psychiatry to address the medical needs and market opportunities in impulsive aggression across several areas (such as attention deficit hyperactivity disorder (ADHD) autism and bipolar disorder) and ADHD. The Company markets its products in the United States through its own specialty sales force and has collaborations with other pharmaceutical companies to license its products outside the United States. Its neurology portfolio consists of Oxtellar XR and Trokendi XR which are indicated for epilepsy in the United States. Its product candidates include Oxtellar XR Trokendi XR SPN-810 SPN-812 and SPN-809.